Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease

Daniela Pugliese, Giuseppe Privitera, Tommaso Schepis, Luigi Larosa, Sara Onali, Sebastiano Onali, Franco Scaldaferri, Antonio Gasbarrini, Flavio Caprioli, Francesca Caprioli, Alessandro Armuzzi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Noninfective drug-related pneumonitis (DRP) is a well-known adverse effect of several drugs: clinical manifestations have mostly an acute/subacute onset and vary from mild to life-threatening. Several DRP cases have been described in patients receiving anti-tumor necrosis factor α, rituximab, and tocilizumab.1,2 To date, only 4 reports of vedolizumab-related pneumonitis have been presented.3-5.
Lingua originaleEnglish
pagine (da-a)e1483-e1487
RivistaClinical Gastroenterology and Hepatology
Volume20
DOI
Stato di pubblicazionePubblicato - 2022

Keywords

  • INFLAMMATORY BOWEL DISEASE
  • VEDOLIZUMAB

Fingerprint

Entra nei temi di ricerca di 'Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease'. Insieme formano una fingerprint unica.

Cita questo